Answers are grounded in this paper and cite their sources.
OBJECTIVES: A higher incidence of autoimmune conditions with greater disease severity is reported post-Coronavirus Disease (COVID). The incidence and disease severity of paediatric autoimmune liver disease (AILD) post-COVID has not been assessed. METHODS: Data on children <16 years of age diagnosed with AILD between 2015 and 2024 from a United Kingdom quaternary liver specialist centre was captured. Comparison of AILD incidence and presenting clinical characteristics in pre and post-COVID pandemic time-periods were made. RESULTS: 199 patients were newly diagnosed with AILD within the study period (82 pre-COVID [2015-2019]; 47 autoimmune hepatitis type 1 [AIH-1], 11 AIH-2, 9 primary sclerosing cholangitis [PSC], 15 overlap/autoimmune sclerosing cholangitis [ASC], and 117 post-COVID [2020-2024]; 64 AIH-1, 10 AIH-2, 20 PSC, 23 overlap/ASC). A sharp rise in the incidence of AIH-1, PSC and overlap syndrome/ASC was observed post-COVID, being most marked in the AIH-1 cohort (p < 0.0001). Children were older at disease presentation for AIH-1, PSC and overlap/ASC compared to pre-COVID, particularly in AIH-1 (p = 0.0093). Minimal variation was observed in AIH-2 patients. Most patients presenting with AIH-1 and overlap/ASC post-COVID did not have a personal history of autoimmunity. High viral coinfection rates were observed in post-COVID AIH-1 and AIH-2 presentations. CONCLUSION: The higher incidence and older presenting age of newly diagnosed AILD patients post-COVID may have resulted from immune dysregulation in susceptible children following the sudden exposure to viral infections after long periods of social isolation, triggering the onset of autoimmunity even in individuals without an autoimmune predisposition.
No takes yet. Share an insight, caveat, or question.
Warner et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: